Skip to main content

Media Releases

Perrigo's media releases will keep you updated on the latest news, product launches, foundation gifts and events across the organization.

Allegan, Michigan – November 19, 2020 – Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, is pleased to announce the fourth year of its “Quitting is Better” campaign in partnership with the American Cancer Society (ACS).

Since 2017, Perrigo has supported the American Cancer Society’s efforts to provide tools and resources for people seeking information, help, and guidance to quit smoking. The ACS is committed to attacking cancer from every angle, which includes helping people quit smoking. Tobacco use is the leading preventable cause of cancer and cancer deaths in the United States. 

This year’s exclusive partnership for Perrigo’s nicotine replacement therapy (NRT) smoking cessation products promises to be the most successful campaign to date with a first-of-its-kind store brand category promotion available to all of the Company’s customers.  As part of the campaign partnership, Perrigo is providing participating retailers with print and digital promotional materials, including on-pack messaging, shelf signage, store displays, store circular advertisements, and digital content to support online offers and loyalty programs.

Allegan, Michigan – November 11, 2020 – Perrigo Company’s Michigan Finance team found a creative way to raise money and give back to an area nonprofit, as organizations face increased funding pressures and canceled fundraiser events due to COVID-19. About 100 Perrigo team members moved their annual volunteer initiative online, raising approximately $36,500 for Kids’ Food Basket’s (KFB) ‘Feeding our Future’ expansion campaign for Allegan and Ottawa counties, where Perrigo manufactures its quality and affordable over-the-counter self-care products. 

Dublin, Ireland – October 27, 2020 – Perrigo Company plc (NYSE; TASE: PRGO), the leading provider of Quality, Affordable Self-Care Products, announced today that it is building a new North American Corporate Headquarters in the heart of Grand Rapids, Michigan. The new headquarters will augment Perrigo’s existing presence in West Michigan, which was established in 1887 and now includes extensive operations in Allegan, Holland and Grand Rapids.

Perrigo’s new offices will be constructed in Michigan State University’s (MSU) expanding Grand Rapids Innovation Park, a public-private partnership that is bringing together academic medicine, healthcare delivery and other partners interested in the transformation of health. The location places Perrigo, the world’s leading over-the-counter health and wellness organization, in the company of academic, research and clinical experts found within the medical park network.

DUBLIN, Sept. 17, 2020-- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to clogging. Perrigo's generic albuterol sulfate inhalation aerosol was developed in partnership with and manufactured by Catalent Pharma Solutions.

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in the U.S. nationwide. Perrigo's abbreviated new drug application ("ANDA") for OTC diclofenac sodium topical gel, 1% is the first store brand ANDA to receive approval from the U.S. Food and Drug Administration.

 

DUBLIN, Aug. 11, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that it will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon®) from Sanofi. Trailing twelve months net sales ending June 30, 2020 for these products were approximately €21 million or approximately $23 million*. Other terms of the transaction were not disclose

DUBLIN, June 19, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has reached a definitive agreement to sell its U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, to a U.K.-headquartered private equity firm for £156 million or approximately $195 million in cash. This transaction, which was signed and closed on the same day, represents another step in Perrigo's transformation to a consumer-focused self-care company.  

 

DUBLIN, June 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it is entering the cannabidiol ("CBD") market through a strategic investment in and long-term supply agreement with Kazmira LLC, a leading supplier of hemp-based CBD products free of tetrahydrocannabinol ("THC-free") based in Watkins, Colorado. The fast-growing and rapidly evolving CBD market is emerging organically in response to changing consumer preferences for natural remedies and aligns with Perrigo's vision "To make lives better by bringing quality, affordable self-care products that consumers trust everywhere they are sold.

Perrigo is one of 36 companies and individuals named as defendants in the most recent complaint filed by various state attorneys general in relation to alleged antitrust violations within the generic pharmaceutical industry. 

A year ago, we launched a new Diversity and Inclusion initiative for Perrigo that stressed the importance of having all members of our community treated with fairness and respect.

Press Inquiries

If you are a member of the press on deadline, please reach out to a member of our Global Investor Relations & Corporate Communications team.

Contact